Securian Asset Management Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Securian Asset Management Inc. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 5,647 shares of the biopharmaceutical company’s stock after selling 250 shares during the quarter. Securian Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $4,023,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. CWA Asset Management Group LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $298,000. Sigma Planning Corp lifted its holdings in Regeneron Pharmaceuticals by 4.1% during the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 16 shares during the last quarter. Nations Financial Group Inc. IA ADV lifted its holdings in Regeneron Pharmaceuticals by 3.5% during the third quarter. Nations Financial Group Inc. IA ADV now owns 1,082 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 37 shares during the last quarter. Entropy Technologies LP purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $420,000. Finally, GSA Capital Partners LLP purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $665,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on REGN. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Bernstein Bank decreased their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. TD Cowen decreased their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Down 4.0 %

Shares of NASDAQ REGN opened at $689.50 on Thursday. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm’s 50 day simple moving average is $696.62 and its two-hundred day simple moving average is $841.12. The stock has a market capitalization of $75.38 billion, a P/E ratio of 18.01, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the business earned $11.86 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.